EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies

Helena Brillembourg, Núria Martínez-Cibrián, Mireia Bachiller, Leticia Alserawan, Valentín Ortiz-Maldonado iD, Sònia Guedan, Julio Delgado iD

British Journal of Haematology · 2024-05 · 204 (5) · 1649-1659

DOI: 10.1111/bjh.19348 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 16.02.2024. Verfasst von Helena Brillembourg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Hospital Clínic, Barcelona, Spain. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agencia Estatal de Investigación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several products containing chimeric antigen receptor T cells targeting CD19 (CART19) have been approved for the treatment of patients with relapsed/refractory non‐Hodgkin's lymphoma (NHL) and acute lymphoblastic leukaemia (ALL). Despite very impressive response rates, a significant percentage of patients experience disease relapse and die of progressive disease. A major cause of CART19 failure is loss or downregulation of CD19 expression in tumour cells, which has prompted a myriad of novel strategies aimed at targeting more than one antigen (e.g. CD19 and CD20 or CD22). Dual targeting can the accomplished through co‐administration of two separate products, co‐transduction with two different vectors, bicistronic cassettes or tandem receptors. In this manuscript, we review the pros and cons of each strategy and the clinical results obtained so far.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveAntigens, CD19HumansLymphoma, B-CellReceptors, Antigen, T-CellT-LymphocytesAntigens, CD20Precursor Cell Lymphoblastic Leukemia-LymphomaAntigens, NeoplasmSialic Acid Binding Ig-like Lectin 2

Stichwörter der Autor:innen

ALLCARCD19CD20CD22NHLdual

Substanzen

Receptors, Chimeric AntigenAntigens, CD19Receptors, Antigen, T-CellAntigens, CD20CD19 molecule, humanAntigens, NeoplasmSialic Acid Binding Ig-like Lectin 2

Autor:innen und Institutionen

  • Department of Haematology, Hospital Clínic, Barcelona, Spain.
  • Oncology and Haematology Area, FRCB-IDIBAPS, Barcelona, Spain.
  • Department of Clinical Pharmacology, Hospital Clínic, Barcelona, Spain.
  • Department of Immunology, Hospital Clínic, Barcelona, Spain.
  • Department of Medicine, University of Barcelona, Barcelona, Spain.
  • CIBERONC, Madrid, Spain.

ORCID-Profile: Valentín Ortiz-Maldonado, Julio Delgado

Förderung

  • Agencia Estatal de Investigación

Zitieren

APA

Brillembourg, H., Martínez-Cibrián, N., Bachiller, M., Alserawan, L., Ortiz-Maldonado, V., Guedan, S., & Delgado, J. (2024). The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies. British Journal of Haematology, 204(5), 1649-1659. https://doi.org/10.1111/bjh.19348

Vancouver

Brillembourg H, Martínez-Cibrián N, Bachiller M, Alserawan L, Ortiz-Maldonado V, Guedan S, et al. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies. British Journal of Haematology. 2024;204(5):1649-1659. doi:10.1111/bjh.19348

BibTeX
@article{Brillembourg2024,
  author = {Brillembourg, Helena and Martínez-Cibrián, Núria and Bachiller, Mireia and Alserawan, Leticia and Ortiz-Maldonado, Valentín and Guedan, Sònia and Delgado, Julio},
  title = {The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {204},
  number = {5},
  pages = {1649--1659},
  doi = {10.1111/bjh.19348}
}
Kostenlos starten →